Oxybutynin: Difference between revisions
(create new note) |
ClaireLewis (talk | contribs) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antispasmodic, urinary | *Type: Antispasmodic, urinary | ||
*Dosage Forms: | *Dosage Forms: 5mg | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
*Common Trade Names: Oxybutynin chloride | *Common Trade Names: Oxybutynin chloride | ||
==Adult Dosing== | ==Adult Dosing== | ||
* | *5mg 2-3 times daily, maximum 5mg 4 times daily | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*> 5 years and adolescent | *> 5 years and adolescent | ||
** | **5mg twice daily, maximum 5mg 3 times daily | ||
==Geriatric Dosing== | ==Geriatric Dosing== | ||
*2. | *2.5mg 2-3 times daily, increase cautiously | ||
==Special Populations== | ==Special Populations== | ||
| Line 28: | Line 28: | ||
*Risk of urinary retention | *Risk of urinary retention | ||
*Risk of gastric retention or severely decreased gastric motility | *Risk of gastric retention or severely decreased gastric motility | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 48: | Line 47: | ||
*Urinary tract infection | *Urinary tract infection | ||
*Blurred vision | *Blurred vision | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 65: | Line 63: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Urology]] | |||
Latest revision as of 00:50, 23 September 2019
Administration
- Type: Antispasmodic, urinary
- Dosage Forms: 5mg
- Routes of Administration: Oral
- Common Trade Names: Oxybutynin chloride
Adult Dosing
- 5mg 2-3 times daily, maximum 5mg 4 times daily
Pediatric Dosing
- > 5 years and adolescent
- 5mg twice daily, maximum 5mg 3 times daily
Geriatric Dosing
- 2.5mg 2-3 times daily, increase cautiously
Special Populations
- Pregnancy Rating: B
- Lactation risk: Not defined, use with caution when administered to a nursing woman
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
- Risk of narrow-angle glaucoma
- Risk of urinary retention
- Risk of gastric retention or severely decreased gastric motility
Adverse Reactions
Serious
- Arrhythmia (sinus)
- Hypotension
- Hypertension
Common
- Dizziness
- Drowsiness
- Xerostomia (dose-related)
- Constipation
- Nausea
- Headache
- Nervousness
- Insomnia
- Urinary hesitancy
- Urinary retention
- Urinary tract infection
- Blurred vision
Pharmacology
- Half-life: 2-3 h
- Metabolism: Liver
- Excretion: Urine
Mechanism of Action
- Direct antispasmodic effect on smooth muscle
- Inhibit action of acetylcholine on smooth muscle; decreased frequency and urgent